Guangdong Taienkang Pharmaceutical Co. Ltd (SHE:301263) — Market Cap & Net Worth
Market Cap & Net Worth: Guangdong Taienkang Pharmaceutical Co. Ltd (301263)
Guangdong Taienkang Pharmaceutical Co. Ltd (SHE:301263) has a market capitalization of $1.50 Billion (CN¥10.28 Billion) as of August 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #7111 globally and #1483 in its home market, demonstrating a 8.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangdong Taienkang Pharmaceutical Co. Ltd's stock price CN¥20.14 by its total outstanding shares 510597000 (510.60 Million). See 301263 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Guangdong Taienkang Pharmaceutical Co. Ltd Market Cap History: 2022 to 2026
Guangdong Taienkang Pharmaceutical Co. Ltd's market capitalization history from 2022 to 2026. Data shows growth from $1.28 Billion to $1.50 Billion (2.48% CAGR).
Guangdong Taienkang Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangdong Taienkang Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.21x
Guangdong Taienkang Pharmaceutical Co. Ltd's market cap is 3.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
75.65x
Guangdong Taienkang Pharmaceutical Co. Ltd's market cap is 75.65 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.28 Billion | $783.48 Million | $174.61 Million | 1.63x | 7.32x |
| 2023 | $1.20 Billion | $760.79 Million | $160.20 Million | 1.57x | 7.46x |
| 2024 | $1.12 Billion | $721.03 Million | $108.22 Million | 1.55x | 10.35x |
| 2025 | $2.17 Billion | $674.90 Million | $28.63 Million | 3.21x | 75.65x |
Competitor Companies of 301263 by Market Capitalization
Companies near Guangdong Taienkang Pharmaceutical Co. Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Guangdong Taienkang Pharmaceutical Co. Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Guangdong Taienkang Pharmaceutical Co. Ltd Historical Marketcap From 2022 to 2026
Between 2022 and today, Guangdong Taienkang Pharmaceutical Co. Ltd's market cap moved from $1.28 Billion to $ 1.50 Billion, with a yearly change of 2.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.50 Billion | -30.53% |
| 2025 | CN¥2.17 Billion | +93.40% |
| 2024 | CN¥1.12 Billion | -6.30% |
| 2023 | CN¥1.20 Billion | -6.49% |
| 2022 | CN¥1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Guangdong Taienkang Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Billion USD |
| MoneyControl | $1.50 Billion USD |
| MarketWatch | $1.50 Billion USD |
| marketcap.company | $1.50 Billion USD |
| Reuters | $1.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the… Read more